PAZ Pharma

PAZ Pharma is a biotechnology company founded in 2019 and headquartered in Mullica Hill, New Jersey, that focuses on the development of novel therapeutic candidates for the treatment of colon cancer. The company specializes in identifying and exploiting the unique metabolic vulnerabilities of cancer cells, aiming to disrupt pathways that are critical for tumor growth and survival. By targeting these specific metabolic mechanisms, the company intends to develop more effective and potentially less toxic treatment options compared to traditional therapies. The research and development pipeline includes both preclinical and clinical-stage candidates designed to address these distinct biological targets.

This work is significant for patients and healthcare providers looking for targeted interventions that move beyond conventional oncology approaches. By concentrating on tumor metabolism, PAZ Pharma seeks to solve the problem of drug resistance and toxic side effects often associated with standard cancer treatments. The organization operates out of the South Jersey Technology Park and focuses its efforts on advancing its lead compounds through critical stages of pharmaceutical development. Through its focused research model, the company aims to contribute to the evolving field of oncology by providing specialized, metabolically-targeted care.